Car-T therapy for hard-to-treat autoimmune diseases
Part of Immune system & allergy clinical trials.
This trial tests whether a patient's own engineered immune cells (called CD19 CAR-T cells) can calm down overactive immune attacks in several autoimmune diseases like lupus, scleroderma, and myositis. It's for people whose disease isn't controlled by standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have a moderate to severe autoimmune disease like lupus, scleroderma, certain forms of vasculitis, myositis, or Sjögren's syndrome that hasn't gotten better with standard medicines.
- Your disease is active despite at least 6 months of standard treatment (for lupus) or 3 months of combination therapy (for other conditions).
- Your organs are working well enough: your blood counts, liver, kidneys, heart, and lungs must be within safe limits for this therapy.
- You agree to use effective birth control during the study and for 2 years after treatment (if you can have children).
- You do not have active cancer, severe infections, or other serious medical conditions that could make this therapy unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized cell therapy (CAR-T) that targets a protein called CD19 on immune cells. It's for people with certain autoimmune diseases like lupus or scleroderma that are still active despite standard treatments. The goal is to see if this therapy can help control the disease when other options haven't worked.
This trial tests whether CAR-T cells, a type of immune cell therapy, can help people with certain autoimmune diseases. If you have lupus, scleroderma, or other listed conditions, you may be able to join and see if this treatment can calm your overactive immune system.
This trial tests whether a special immune cell treatment (CD19 CAR-T) can help people with certain severe autoimmune diseases that have not improved with standard therapies. It is a very early study to see if the treatment is safe and effective for conditions like lupus, systemic sclerosis, vasculitis, myositis, or Sjögren's syndrome.
This trial tests a special immune cell therapy (CAR T cells) for people with severe lupus, Sjogren's syndrome, systemic sclerosis, and other autoimmune conditions that haven't improved with standard treatments. The therapy is designed to target and reset the immune system.
This trial tests a new CAR-T cell therapy that targets two proteins (CD19 and BCMA) on immune cells. It is for people with certain autoimmune diseases (like lupus or scleroderma) that have not responded well to standard treatments or have relapsed after prior cell therapy.
This trial tests a new treatment using your own immune cells (CAR T-cells) targeting a protein called CD19 to control severe autoimmune diseases like lupus, Sjogren's, scleroderma, dermatomyositis, or vasculitis. The goal is to see if it's safe and can improve symptoms when other treatments haven't worked.
Hear when a new Autoimmune Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.